Alpha 1-blocking properties of carvedilol during acute and chronic administration
- PMID: 1378144
- DOI: 10.1097/00005344-199219001-00005
Alpha 1-blocking properties of carvedilol during acute and chronic administration
Abstract
Carvedilol is a beta-adrenergic-blocking drug with vasodilating properties. This vasodilation has been ascribed to alpha 1-adrenergic blockade, but it has never been shown in the clinical setting. We addressed this issue by studying eight patients with mild essential hypertension who were given prazosin, 2 mg or carvedilol, 25 mg p.o. following a 2-week washout from previous treatment, according to a randomized double-blind, crossover experimental design. Before and 2 h after the administration of either prazosin or carvedilol, the patients were infused i.v. with increasing doses of phenylephrine (0.2-1.2 microgram/kg/min) and isoproterenol (0.01-0.05 microgram/kg/min). The patients were thereafter maintained on carvedilol 25 mg daily for 3 weeks, and the i.v. phenylephrine and isoproterenol infusions were repeated 2 h after the last tablet administration. The results showed that the single dose of carvedilol and prazosin lowered blood pressure (beat-to-beat finger pressure measurement) to a similar extent, but that heart rate was unaffected by prazosin and reduced by carvedilol. The tachycardic response to isoproterenol was abolished by carvedilol and unaffected by prazosin, whereas the pressor response to phenylephrine was reduced by carvedilol and virtually abolished by prazosin. The antihypertensive, beta-blocking and alpha 1-adrenergic-blocking effects of carvedilol were unchanged following prolonged administration of the drug. Thus, at a clinically effective dose, carvedilol not only has beta- but also sizeable alpha 1-blocking effects. These effects are preserved during prolonged administration of the drug. For a comparable antihypertensive action, however, the alpha 1-blocking effect is less pronounced than that of an alpha 1-blocker such as prazosin.
Similar articles
-
The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man.Br J Clin Pharmacol. 1995 Jul;40(1):19-23. doi: 10.1111/j.1365-2125.1995.tb04529.x. Br J Clin Pharmacol. 1995. PMID: 8527263 Free PMC article. Clinical Trial.
-
Single and repeated doses of the vasodilator/beta-adrenergic antagonist, carvedilol, block cirazoline- and isoproterenol-mediated hemodynamic responses in the conscious rat.Cardiovasc Drugs Ther. 1992 Oct;6(5):499-504. doi: 10.1007/BF00055608. Cardiovasc Drugs Ther. 1992. PMID: 1360255
-
Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine.Drugs. 1988;36 Suppl 6:37-47. doi: 10.2165/00003495-198800366-00008. Drugs. 1988. PMID: 2908303 Clinical Trial.
-
Vasodilatory action of carvedilol.J Cardiovasc Pharmacol. 1992;19 Suppl 1:S5-11. doi: 10.1097/00005344-199219001-00003. J Cardiovasc Pharmacol. 1992. PMID: 1378150 Review.
-
Pharmacodynamic profile of carvedilol.Cardiology. 1993;82 Suppl 3:19-23. doi: 10.1159/000175939. Cardiology. 1993. PMID: 8106159 Review.
Cited by
-
Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.Int J Mol Sci. 2021 May 28;22(11):5783. doi: 10.3390/ijms22115783. Int J Mol Sci. 2021. PMID: 34071350 Free PMC article. Review.
-
Drug screening with zebrafish visual behavior identifies carvedilol as a potential treatment for an autosomal dominant form of retinitis pigmentosa.Sci Rep. 2021 Jun 1;11(1):11432. doi: 10.1038/s41598-021-89482-z. Sci Rep. 2021. PMID: 34075074 Free PMC article.
-
Hemodynamic effects of one week of carvedilol administration on cirrhotic rats.J Gastroenterol. 2006 Apr;41(4):361-8. doi: 10.1007/s00535-006-1782-5. J Gastroenterol. 2006. PMID: 16741616
-
Prazosin initiation and dose titration in a patient with posttraumatic stress disorder on concurrent carvedilol.Ment Health Clin. 2019 Sep 4;9(5):326-330. doi: 10.9740/mhc.2019.09.326. eCollection 2019 Sep. Ment Health Clin. 2019. PMID: 31534876 Free PMC article.
-
The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man.Br J Clin Pharmacol. 1995 Jul;40(1):19-23. doi: 10.1111/j.1365-2125.1995.tb04529.x. Br J Clin Pharmacol. 1995. PMID: 8527263 Free PMC article. Clinical Trial.